• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Emergency

Early alteplase treatment leads to better stroke outcomes regardless of age or stroke severity

byDevin MillerandStefan Trela
August 6, 2014
in Emergency, Neurology
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. Alteplase (recombinant tissue plasminogen activator, or rtPA) administration within 4.5 hours hours following the onset of an ischemic stroke improves the odds of good stroke outcomes regardless of age or stroke severity, with greater proportional benefits seen with earlier treatment. 

2. Administration of alteplase carried an increased risk of fatal intracranial hemorrhage within the first few days following treatment. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Intravenous administration of alteplase within 4.5 hours following the onset of an ischemic stroke has been shown to be beneficial in many patients. Controversy exists, however, regarding alteplase treatment either within 3 or 4.5 hours, after 4.5 hours, in patients greater than 80 years of age, or in patients with mild or severe strokes. This study aimed to clarify these controversies by utilizing a meta-analysis that combined data from several large randomized trials comparing alteplase with placebo or open control.

The results showed that alteplase can be used in patients of any age group or stroke severity up to 4.5 hours after ischemic stroke onset with greater proportional benefits seen with earlier treatment. However, treatment with alteplase also led to increased risks of fatal intracranial hemorrhage within the first few days following treatment. Strengths of this analysis include its large study population as well as that individual data sets could be extracted for many of these patients. Additionally, the large number of patients over the age of 80 allowed for better representation of the general population and comparison to treatment in patients under 80 years of age. A drawback to this study is that the estimates of intracranial hemorrhage may be exaggerated due to broad definition utilized by one of the studies included in the analysis. The authors conclude that despite early increased risks of fatal intracranial hemorrhage, alteplase significantly improves the long-term odds of a good stroke outcome at 3-6 months.

This study was funded by the UK Medical Research Council, British Heart Foundation, University of Glasgow, and University of Edinburgh

RELATED REPORTS

In selected patients with anterior-circulation large-vessel stroke 24-72 hours after onset, thrombectomy improved 90-day function but increased hemorrhage and death

Cannabis use, including smoked or edible, linked to higher stroke risk

Click to read the study, published today in The Lancet

Relevant Reading: The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

FDA approvedFor stroke: Sunharbo (asundexian), Nov 9, 2026→

In-Depth [meta-analysis]: This meta-analysis included data from 6,756 different patients from nine randomized phase 3 trials. Primary measure of treatment efficacy was the proportion of patients with a good stroke outcome, defined as a modified Rankin Score of 0 or 1 (symptom free or residual symptoms without loss of activity) at 3-6 months. Symptomatic intracranial hemorrhage within 7 days of treatment, fatal intracranial hemorrhage within 7 days, and 90-day mortality were assessed as secondary outcomes.

Overall, 2,110 (31%) of 6,756 patients achieved a good stroke outcome at 3-6 months. Alteplase resulted in greater odds of a good outcome, with earlier treatment resulting in a greater proportional benefit (p=0.016). The time at which alteplase was estimated to have no effect was 6.3 hours (95% Confidence Interval [CI] 5.0-13.8). Alteplase treatment resulted in a good outcome for 259 (32.9%) of 787 patients treated within 3.0 hours vs. 176 (23.1%) of 762 controls (Odds Ration [OR] 1.75, 95% CI 1.35-2.27); 485 (35.3%) of 1,375 patients treated between 3.0-4.5 hours vs. 432 (30.1%) of 1,437 controls (OR 1.26, 95% CI 1.05-1.51); and 401 (32.5%) of 1,229 patients treated greater than 4.5 hours vs. 357 (30.6%) of 1,166 controls (OR 1.15, 95% CI 0.95-1.40). All treatment benefits were similar regardless of patient age or stroke severity. 231 (6.8%) of 3,391 alteplase patients experienced type 2 parenchymal hemorrhages as compared to 44 (1.3%) of 3,365 controls (OR 5.55, 95% CI 4.01-7.70, p<0.0001) within 7 days, and 91 (2.7%) alteplase patients vs. 13 (0.4%) controls experienced fatal intracranial hemorrhage (OR 7.14, 95% CI 3.98-12.79, p<0.0001). The increase in risk of fatal intracranial hemorrhage was similar regardless of delay in treatment, age, or stroke severity.

More from this author: Improved hematologic cancer survival in Europe over a 15 year period [EUROCARE-5 study];Vitamin D may reduce the risk of hypertension;Schizophrenia linked with higher rates of violence, suicide, and early mortality;Overall improvement in management of high blood pressure between 1994 and 2011;Link between early life antibiotic use, asthma exacerbations, and impaired viral immunity 

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: alteplasestroketpa
Previous Post

One-time telephone interventions have little effect on drug abuse

Next Post

BCG vaccine protective against active tuberculosis in children

RelatedReports

Stroke treatment collage: an engraved brain with teal arteries and one blocked branch, a coiled catheter and a stopwatch
Emergency

In selected patients with anterior-circulation large-vessel stroke 24-72 hours after onset, thrombectomy improved 90-day function but increased hemorrhage and death

November 7, 2026
Cannabis and mental health collage: a thoughtful young man with curly hair, a flat cannabis leaf and three blank shopfronts
Cardiology

Cannabis use, including smoked or edible, linked to higher stroke risk

November 6, 2026
Ischemic stroke collage: an engraved brain with one artery traced in teal and a small clot lifted away on a ribbon
Neurology

Intra-arterial alteplase after thrombectomy improves three-month functional recovery in large vessel stroke

May 26, 2026
Blood clots collage: a cutaway vein where a fibrin mesh unravels among red blood cells, an engraved eye and a pill bottle
Neurology

Tenecteplase not associated with visual improvement in central retinal artery occlusion

January 28, 2026
Next Post

BCG vaccine protective against active tuberculosis in children

ACP endorses polysomnography over portable monitors for diagnosing sleep apnea

PALB2 mutations shown to be important risk factor for breast cancer

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Removing Race and Ethnicity From Dialysis Mortality Risk Adjustment Changes Facility Performance Rankings
  • AI Model Shows Promise in Predicting PTSD Risk Following Trauma
  • 2 Minute Medicine Rewind November 16, 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.